In a research report published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) with a $422 price target, as the company …
In a research report issued today, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN), and raised his price …
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and slightly raised his price target to $390 (from …
Regeneron Pharmaceuticals (REGN) announced that Eylea has been approved by the European Commission for use in patients with DME. Marketing of Eylea will be initiated …
Yesterday, Regeneron Pharmaceuticals (REGN) announced second-quarter results, posting EPS of $0.82.
Yesterday, Roth Capital analyst Joseph Pantginis issued a note in which he reiterated a Buy rating on Regeneron Pharmaceuticals (REGN) and raised his …
On Friday, Regeneron Pharmaceuticals (REGN) announced results from the Phase III VIVID-DME study of Eylea in DME that showed that treatment with Eylea 2 mg dosed …
In a research note released today, Roth Capital analyst Joseph Pantginis reiterated coverage with a Buy rating on shares of Regeneron Pharmaceuticals (REGN) and a $382 price target, after REGN and partner …
In a research note released Monday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Regeneron Pharmaceuticals, Inc. (REGN) and a price target of $382.
In a research note released this morning, Roth Capital reiterated coverage on Regeneron Pharmaceuticals (REGN) with a Buy rating and a price target of $382.00, following the announcement that …
